Hormone Resistant Prostate Cancer Completed Phase 2 Trials for Prednisone (DB00635)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00541281Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic CancerTreatment
NCT01503229Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment